In late October 2025, Point32Health, Massachusetts’ second-largest health insurer, announced its second major round of ...
Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication ...
el agonista del GLP-1 de Eli Lilly comercializado como Mounjaro para el tratamiento de la diabetes y Zepbound para la pérdida de peso, afecta los síntomas durante un período de 12 meses. «Se ha ...
The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.
Plus, the Trump administration is expected to release finalized Medicare payment rules for doctors and hospitals as soon as ...
Wegovy Zepbound cost-effectiveness report finds both drugs remain valuable at higher prices despite affordability concerns, per ICER analysis.
Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...
TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...
Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...
Major stock indexes declined Thursday as investors digested several big tech earnings reports and awaited more after the ...
The U.S. stock market sank from its record heights Thursday, as Wall Street sifted through mixed developments on everything from the U.S.-China trade war to profits for Big Tech behemoths. The S&P 500 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback